KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Cost of Revenue (2017 - 2025)

Bionano Genomics' Cost of Revenue history spans 7 years, with the latest figure at $4.0 million for Q3 2025.

  • For Q3 2025, Cost of Revenue fell 72.47% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $15.5 million, down 54.27%, while the annual FY2024 figure was $30.4 million, 14.49% up from the prior year.
  • Cost of Revenue for Q3 2025 was $4.0 million at Bionano Genomics, up from $3.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $14.5 million in Q3 2024 and bottomed at $2.1 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $5.2 million (2022), against an average of $5.5 million.
  • The largest annual shift saw Cost of Revenue surged 300.83% in 2021 before it plummeted 72.47% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $6.1 million in 2021, then rose by 5.72% to $6.4 million in 2022, then grew by 29.22% to $8.3 million in 2023, then crashed by 42.7% to $4.7 million in 2024, then decreased by 15.78% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Cost of Revenue are $4.0 million (Q3 2025), $3.3 million (Q2 2025), and $3.5 million (Q1 2025).